quisinostat

Quisinostat is an orally bioavailable, second-generation, hydroxamic acid-based small molecule inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. It acts by inhibiting HDACs—particularly class I and II isoforms—leading to the accumulation of highly acetylated histones. This results in chromatin remodeling, inhibition of tumor suppressor gene transcription repression, cell cycle arrest (notably G0/G1 phase), and induction of apoptosis in tumor cells. Quisinostat has demonstrated preclinical and clinical activity against various cancers including lymphoma, myelodysplastic syndromes, advanced or refractory leukemia, cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome), hepatocellular carcinoma, non-small cell lung cancer (NSCLC), ovarian cancer, multiple myeloma (in combination regimens), and glioblastoma as a radiosensitizer. The drug was originally developed by Janssen Pharmaceuticals and later licensed to NewVac LLC[1][2][3][4][5][6][7][8].

Brand names

AvionkoАВИОНКО

Other names

quisinostat